BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bueno de Mesquita M, Ferrante M, Henckaerts L, Joossens M, Janssens V, Hlavaty T, Pierik M, Joossens S, Van Schuerbeek N, Van Assche G. Clustering of (auto)immune diseases with early-onset and complicated inflammatory bowel disease. Eur J Pediatr. 2009;168:575-583. [PMID: 18670786 DOI: 10.1007/s00431-008-0798-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Attauabi M, Zhao M, Bendtsen F, Burisch J. Systematic Review with Meta-analysis: The Impact of Co-occurring Immune-mediated Inflammatory Diseases on the Disease Course of Inflammatory Bowel Diseases. Inflamm Bowel Dis 2021;27:927-39. [PMID: 32628745 DOI: 10.1093/ibd/izaa167] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
2 Kansal S, Catto-Smith AG, Boniface K, Thomas S, Cameron DJ, Oliver M, Alex G, Kirkwood CD, Wagner J. Variation of Gut Mucosal Microbiome With Anti-Saccharomyces cerevisiae Antibody Status in Pediatric Crohn Disease. J Pediatr Gastroenterol Nutr 2019;69:696-703. [PMID: 31764438 DOI: 10.1097/MPG.0000000000002461] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
3 Al-barghouthy EY, Abuhammad A, Taha MO. QSAR-guided pharmacophore modeling and subsequent virtual screening identify novel TYK2 inhibitor. Med Chem Res 2019;28:1368-87. [DOI: 10.1007/s00044-019-02377-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
4 Lee WS, Ng RT, Chan KW, Lau YL. Variable outcome in infantile-onset inflammatory bowel disease in an Asian cohort. World J Gastroenterol 2016; 22(48): 10653-10662 [PMID: 28082818 DOI: 10.3748/wjg.v22.i48.10653] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
5 Cheng Y, Zhu Y, Huang X, Zhang W, Han Z, Liu S. Association between TLR2 and TLR4 Gene Polymorphisms and the Susceptibility to Inflammatory Bowel Disease: A Meta-Analysis. PLoS One. 2015;10:e0126803. [PMID: 26023918 DOI: 10.1371/journal.pone.0126803] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
6 Rinaldi M, Perricone R, Blank M, Perricone C, Shoenfeld Y. Anti-Saccharomyces cerevisiae autoantibodies in autoimmune diseases: from bread baking to autoimmunity. Clin Rev Allergy Immunol 2013;45:152-61. [PMID: 23292495 DOI: 10.1007/s12016-012-8344-9] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 5.8] [Reference Citation Analysis]
7 Liang J, van Abbema A, Balazs M, Barrett K, Berezhkovsky L, Blair W, Chang C, Delarosa D, DeVoss J, Driscoll J, Eigenbrot C, Ghilardi N, Gibbons P, Halladay J, Johnson A, Kohli PB, Lai Y, Liu Y, Lyssikatos J, Mantik P, Menghrajani K, Murray J, Peng I, Sambrone A, Shia S, Shin Y, Smith J, Sohn S, Tsui V, Ultsch M, Wu LC, Xiao Y, Yang W, Young J, Zhang B, Zhu BY, Magnuson S. Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors. J Med Chem 2013;56:4521-36. [PMID: 23668484 DOI: 10.1021/jm400266t] [Cited by in Crossref: 53] [Cited by in F6Publishing: 56] [Article Influence: 5.3] [Reference Citation Analysis]
8 Henderson P, van Limbergen JE, Wilson DC, Satsangi J, Russell RK. Genetics of childhood-onset inflammatory bowel disease. Inflamm Bowel Dis 2011;17:346-61. [PMID: 20839313 DOI: 10.1002/ibd.21283] [Cited by in Crossref: 50] [Cited by in F6Publishing: 55] [Article Influence: 4.2] [Reference Citation Analysis]